PMID- 16516129
OWN - NLM
STAT- MEDLINE
DCOM- 20060718
LR  - 20071115
IS  - 1521-6926 (Print)
IS  - 1521-6926 (Linking)
VI  - 19
IP  - 2
DP  - 2006
TI  - Are matched unrelated donor transplants justified for AML in CR1?
PG  - 321-8
AB  - There has been controversy about the optimal consolidation therapy for patients 
      with acute myeloid leukemia (AML) in first remission. Hematopoietic stem cell 
      transplantation from human leukocyte antigen (HLA)-identical siblings has 
      improved the survival of patients with unfavorable cytogenetics, but has not 
      improved the survival of intermediate- or favorable-risk patients. If an 
      HLA-identical sibling donor is not available, alternative sources of stem cells 
      may be sought. HLA mismatched transplants are associated with an increased risk 
      of graft rejection and graft-versus-host disease, and lower survival. Since large 
      registries of HLA-typed volunteer donors have been established and the newer and 
      more sensitive tissue typing technology can more clearly differentiate between 
      matched and unmatched donors, some AML patients without an HLA-matched sibling 
      have received transplants from an HLA-matched unrelated donor while in first 
      remission. Data from the Center for International Blood and Marrow Transplant 
      Research indicate that survival of patients with unfavorable cytogenetics appears 
      at least as good with unrelated donor grafts as previously reported for matched 
      sibling grafts, and better than consolidation chemotherapy. AML patients in first 
      remission with unfavorable cytogenetics without a matched family donor should be 
      offered an unrelated donor transplant.
FAU - Anasetti, Claudio
AU  - Anasetti C
AD  - University of South Florida; H. Lee Moffitt Cancer Center and Research Institute, 
      Tampa, FL 33612 USA. anasetc@moffitt.usf.edu
FAU - Perkins, Janelle
AU  - Perkins J
FAU - Nieder, Michael L
AU  - Nieder ML
FAU - Field, Teresa
AU  - Field T
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Best Pract Res Clin Haematol
JT  - Best practice & research. Clinical haematology
JID - 101120659
SB  - IM
MH  - Cytogenetics/methods
MH  - Databases, Factual
MH  - Disease-Free Survival
MH  - *Donor Selection/methods
MH  - Histocompatibility Testing/methods
MH  - Humans
MH  - Leukemia, Myeloid, Acute/mortality/*therapy
MH  - *Living Donors
MH  - Siblings
MH  - *Transplantation Conditioning/methods/mortality
MH  - Transplantation, Homologous
RF  - 15
EDAT- 2006/03/07 09:00
MHDA- 2006/07/19 09:00
CRDT- 2006/03/07 09:00
PHST- 2006/03/07 09:00 [pubmed]
PHST- 2006/07/19 09:00 [medline]
PHST- 2006/03/07 09:00 [entrez]
AID - S1521-6926(05)00125-8 [pii]
AID - 10.1016/j.beha.2005.12.002 [doi]
PST - ppublish
SO  - Best Pract Res Clin Haematol. 2006;19(2):321-8. doi: 10.1016/j.beha.2005.12.002.